Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Design, synthesis and anticancer activity of novel 2-arylbenzimidazole/2-thiopyrimidines and 2-thioquinazolin-4(3H)-ones conjugates as targeted RAF and VEGFR-2 kinases inhibitors
Islam H. Ali, Heba T. Abdel‐Mohsen, Marwa M. Mounier, et al.
Bioorganic Chemistry (2022) Vol. 126, pp. 105883-105883
Closed Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Recent development of multi-target VEGFR-2 inhibitors for the cancer therapy
Xiujuan Liu, Hong-Cheng Zhao, Su-Juan Hou, et al.
Bioorganic Chemistry (2023) Vol. 133, pp. 106425-106425
Closed Access | Times Cited: 62
Receptor-based pharmacophore modeling, molecular docking, synthesis and biological evaluation of novel VEGFR-2, FGFR-1, and BRAF multi-kinase inhibitors
Heba T. Abdel‐Mohsen, Marwa Ibrahim, Amira M. Nageeb, et al.
BMC Chemistry (2024) Vol. 18, Iss. 1
Open Access | Times Cited: 12
Novel thiazolidin-4-one benzenesulfonamide hybrids as PPARγ agonists: Design, synthesis and in vivo anti-diabetic evaluation
Islam H. Ali, Rasha M. Hassan, Ahmed M. El Kerdawy, et al.
European Journal of Medicinal Chemistry (2024) Vol. 269, pp. 116279-116279
Closed Access | Times Cited: 11
Recent Advances in Structural Optimization of Quinazoline-Based Protein Kinase Inhibitors for Cancer Therapy (2021–Present)
Heba T. Abdel‐Mohsen, Manal M. Anwar, Nesreen S. Ahmed, et al.
Molecules (2024) Vol. 29, Iss. 4, pp. 875-875
Open Access | Times Cited: 9
Benzimidazole-oxindole hybrids as multi-kinase inhibitors targeting melanoma
Rasha M. Allam, Ahmed M. El Kerdawy, Ahmed Gouda, et al.
Bioorganic Chemistry (2024) Vol. 146, pp. 107243-107243
Closed Access | Times Cited: 9
Design, synthesis, antineoplastic activity of new pyrazolo[3,4-d]pyrimidine derivatives as dual CDK2/GSK3β kinase inhibitors; molecular docking study, and ADME prediction
Mohamed T. M. Nemr, Ahmed Elshewy, Mohammed L. Ibrahim, et al.
Bioorganic Chemistry (2024) Vol. 150, pp. 107566-107566
Closed Access | Times Cited: 9
New pyrazolylindolin-2-one based coumarin derivatives as anti-melanoma agents: design, synthesis, dual BRAFV600E/VEGFR-2 inhibition, and computational studies
Ahmed Sabt, Mohammed A. Khedr, Wagdy M. Eldehna, et al.
RSC Advances (2024) Vol. 14, Iss. 9, pp. 5907-5925
Open Access | Times Cited: 7
Quinazoline‐oxindole hybrids as angiokinase inhibitors and anticancer agents: Design, synthesis, biological evaluation, and molecular docking studies
Yasmin M. Syam, Somaia S. Abd El‐Karim, Heba T. Abdel‐Mohsen
Archiv der Pharmazie (2024) Vol. 357, Iss. 10
Closed Access | Times Cited: 6
Benzimidazole‐oxindole hybrids: A novel class of selective dual CDK2 and GSK‐3β inhibitors of potent anticancer activity
Heba T. Abdel‐Mohsen, Yasmin M. Syam, Mahmoud S. Abd El‐Ghany, et al.
Archiv der Pharmazie (2024) Vol. 357, Iss. 10
Closed Access | Times Cited: 5
Novel benzenesulfonamides as dual VEGFR2/FGFR1 inhibitors targeting breast cancer: Design, synthesis, anticancer activity and in silico studies
Rasha M. Hassan, Islam H. Ali, Ahmed M. El Kerdawy, et al.
Bioorganic Chemistry (2024) Vol. 152, pp. 107728-107728
Closed Access | Times Cited: 5
Design and synthesis of new quinazolinone derivatives: investigation of antimicrobial and biofilm inhibition effects
Rasha M. Hassan, Heba Yehia, Mohammed Farrag El‐Behairy, et al.
Molecular Diversity (2024)
Open Access | Times Cited: 4
Recent Advances and Future Directions on Small Molecule VEGFR Inhibitors in Oncological Conditions
Amandeep Thakur, Mandeep Rana, Anshul Mishra, et al.
European Journal of Medicinal Chemistry (2024) Vol. 272, pp. 116472-116472
Closed Access | Times Cited: 3
Diphenyl urea‐benzylidene acetohydrazide hybrids as fibroblast growth factor receptor 1 inhibitors and anticancer agents
Heba T. Abdel‐Mohsen, Amira M. Nageeb, Iman A. Y. Ghannam
Drug Development Research (2024) Vol. 85, Iss. 6
Closed Access | Times Cited: 3
Synthetic non-toxic anti-biofilm agents as a strategy in combating bacterial resistance
Rasha M. Hassan, Mohamed Samir Abd El-Maksoud, Iman A. Y. Ghannam, et al.
European Journal of Medicinal Chemistry (2023) Vol. 262, pp. 115867-115867
Closed Access | Times Cited: 8
New series of 4,6-diaryl pyrimidines: facile synthesis and antiproliferative activity as dual EGFR/VEGFR-2 inhibitors
Yaser A. Mostafa, Abdeljalil Assoud, Ahmed Desoky, et al.
Frontiers in Chemistry (2024) Vol. 12
Open Access | Times Cited: 2
An updated literature on BRAF inhibitors (2018–2023)
Lalmohan Maji, Ghanshyam Teli, Nulgumnalli Manjunathaiah Raghavendra, et al.
Molecular Diversity (2023) Vol. 28, Iss. 4, pp. 2689-2730
Closed Access | Times Cited: 7
Benzimidazole‐Containing Compounds as Anticancer Agents
Ulviye Acar Çevik, Ayşen Işık, Betül Kaya, et al.
ChemistrySelect (2024) Vol. 9, Iss. 32
Closed Access | Times Cited: 1
Novel 2‐oxo‐2‐phenylethoxy and benzyloxy diaryl urea hybrids as VEGFR‐2 inhibitors: Design, synthesis, and anticancer evaluation
Iman A. Y. Ghannam, Ahmed M. El Kerdawy, Marwa M. Mounier, et al.
Archiv der Pharmazie (2022) Vol. 356, Iss. 2
Closed Access | Times Cited: 9
Design, synthesis, in-vitro biological screening and in-silico studies of 2-thioxodihydropyrimidinone based new aminomethylene scaffolds
Muhammad Naeem Ayyaz, Muhammad Sarfraz, Muhammad Arshad, et al.
Journal of Molecular Structure (2023) Vol. 1299, pp. 137153-137153
Closed Access | Times Cited: 5
New benzimidazole‐oxadiazole derivatives as potent VEGFR‐2 inhibitors: Synthesis, anticancer evaluation, and docking study
Ulviye Acar Çevik, İsmail Çeli̇k, Şennur Görgülü, et al.
Drug Development Research (2024) Vol. 85, Iss. 4
Open Access | Times Cited: 1
Benzimidazole–dioxoisoindoline conjugates as dual VEGFR-2 and FGFR-1 inhibitors: design, synthesis, biological investigation, molecular docking studies and ADME predictions
Heba T. Abdel‐Mohsen, Amira M. Nageeb
RSC Advances (2024) Vol. 14, Iss. 39, pp. 28889-28903
Open Access | Times Cited: 1
Discovery of novel diaryl urea-oxindole hybrids as BRAF kinase inhibitors targeting BRAF and KRAS mutant cancers
Iman A. Y. Ghannam, Ahmed M. El Kerdawy, Marwa M. Mounier, et al.
Bioorganic Chemistry (2024) Vol. 153, pp. 107848-107848
Closed Access | Times Cited: 1
Chalcone/1,3,4-Oxadiazole/Benzimidazole hybrids as novel anti-proliferative agents inducing apoptosis and inhibiting EGFR & BRAFV600E
Fatma Fouad Hagar, Samar H. Abbas, Hesham A. M. Gomaa, et al.
BMC Chemistry (2023) Vol. 17, Iss. 1
Open Access | Times Cited: 4
Synthesis of Imidazole‐2,3‐dihydrothiazole Compounds as VEGFR‐2 Inhibitors and Their Support with in Silico Studies
Derya Osmani̇ye, Nurnehir BALTACİ, Berkant Kurban, et al.
Chemistry & Biodiversity (2023) Vol. 20, Iss. 9
Closed Access | Times Cited: 2
Design, synthesis, and in silico insights of novel N’-(2-oxoindolin-3-ylidene)piperidine-4-carbohydrazide derivatives as VEGFR-2 inhibitors
Wagdy M. Eldehna, Youmna A Habib, Abeer E. Mahmoud, et al.
Bioorganic Chemistry (2024) Vol. 153, pp. 107829-107829
Closed Access
Page 1 - Next Page

Scroll to top